固定剂量复方氨氯地平/塞来昔布（Consensi）治疗高血压和骨关节炎。
Fixed-Dose Combination Amlodipine/Celecoxib (Consensi) for Hypertension and Osteoarthritis.
机构信息
Department of Pharmacotherapy & Translational Research, College of Pharmacy, University of Florida, Gainesville.
Department of Pharmacotherapy & Translational Research, College of Pharmacy, University of Florida, Gainesville.
出版信息
Am J Med. 2019 Feb;132(2):172-174. doi: 10.1016/j.amjmed.2018.08.027. Epub 2018 Sep 18.
The US Food and Drug Administration recently granted an approved indication for the first fixed-dose combination antihypertensive (amlodipine) and nonsteroidal anti-inflammatory drug (celecoxib) for treatment of comorbid hypertension and osteoarthritis. This review summarizes available data on this combination product, to be marketed as Consensi (Kitov Pharmaceuticals, Ltd, Tel Aviv, Israel), and discusses its potential place in therapy.
美国食品和药物管理局最近批准了首个固定剂量复方降压药（氨氯地平）和非甾体抗炎药（塞来昔布）用于治疗共病高血压和骨关节炎。这篇综述总结了即将上市的 Consensi（Kitov Pharmaceuticals，Ltd，以色列特拉维夫）这一复方制剂的现有数据，并讨论了其在治疗中的潜在地位。
Zotero 插件